Subsequently, the down-regulation of METTL3 also reduces FSP1 m6A modification and FSP1-mediated ferroptosis, and ultimately increases the cisplatin resistance of NSCLC cell lines [36]. The gene discussed is METTL3; the disease is non-small cell lung carcinoma.